Kenvue Inc. (KVUE)
NYSE: KVUE · Real-Time Price · USD
23.78
+0.09 (0.38%)
At close: Nov 20, 2024, 4:00 PM
23.74
-0.04 (-0.17%)
Pre-market: Nov 21, 2024, 7:00 AM EST

Company Description

Kenvue Inc. operates as a consumer health company worldwide.

The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health.

The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee’s, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

The Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX brand names.

The Essential Health segment offers oral and baby, women’s health, wound, and other care products under the Listerine, Johnson’s, Band-Aid, and Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash brands.

The company was incorporated in 2022 and is headquartered in Skillman, New Jersey.

Kenvue Inc.
Kenvue logo
Country United States
Founded 2022
IPO Date May 4, 2023
Industry Household & Personal Products
Sector Consumer Staples
Employees 22,000
CEO Thibaut Mongon

Contact Details

Address:
199 Grandview Road
Skillman, New Jersey 08558
United States
Phone 908 874 1200
Website kenvue.com

Stock Details

Ticker Symbol KVUE
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
IPO Price $22.00
CIK Code 0001944048
CUSIP Number 49177J102
ISIN Number US49177J1025
Employer ID 88-1032011
SIC Code 2844

Key Executives

Name Position
Thibaut Mongon Chief Executive Officer and Director
Paul Ruh Chief Financial Officer
Meredith Stevens Chief Operations Officer
Carlton Lawson Group President of EMEA and Latin America
Ellie Bing Xie Group President of Asia Pacific
Heather R. Howlett Chief Accounting Officer
Bernardo Tavares Chief Data and Technology Officer
Dr. Caroline Tillett Ph.D. Chief Scientific Officer
Tina Romani Head of Investor Relations
Matthew Orlando General Counsel

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 7, 2024 10-Q Quarterly Report
Nov 7, 2024 8-K Current Report
Oct 24, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 16, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Sep 10, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Aug 6, 2024 10-Q Quarterly Report
Aug 6, 2024 8-K Current Report
Jul 31, 2024 8-K Current Report